LENZ Therapeutics Inc
Research LENZ Therapeutics Inc (LENZ) on Bullrun: market cap USD 146.72M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLENZ
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 146.72M
- Financial periodQ1 2026
- RevenueUSD 1.90M
- Net income-USD 41.49M
- Free cash flow-USD 33.60M
- Gross margin43.4%
Valuation Snapshot
latest market cap is USD 146.72M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 19.09M | -USD 82.13M | -USD 70.00M | 97.8% | -2.85 | USD 25.18M | USD 815.00K | USD 284.34M |
| FY2024 | USD 0 | -USD 49.77M | -USD 59.86M | n/a | -2.34 | USD 20.16M | USD 1.38M | USD 204.08M |
| FY2023 | USD 0 | -USD 69.97M | -USD 60.41M | n/a | -35.71 | USD 35.14M | USD 329.00K | -USD 92.71M |
| FY2022 | n/a | -USD 101.05M | -USD 94.57M | n/a | -1.84 | USD 47.73M | USD 250.00K | -USD 24.17M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 146.72M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 501.52M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 794.46M | n/a | 49.9% | 14.42 |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2024 | 14.42 USD |
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LENZ Therapeutics Inc's market cap?
LENZ Therapeutics Inc's market capitalization is USD 146.72M.
What does LENZ Therapeutics Inc do?
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.